Making better decisions in drug discovery is not down to implementing more tools. Here, Dr Harsh Shah reveals why teams must start by defining the scientific question.
Stronger binding isn’t always better. Dr Teresa Barata of FairJourney Bio explains how researchers engineered a dual-specificity antibody switch designed to control IL-12 activity in tumours.
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
The Rainwater Charitable Foundation has awarded more than $1m through its Sprint to Lead programme to support three one-year projects targeting tau protein in primary tauopathies, including PSP, CBD and FTD.
A postage stamp-sized microsystem incorporating cancer cells, blood vessel-like structures and nerves could transform how researchers study tumour growth, metastasis and treatment resistance in head and neck cancer.
Researchers at the University of Virginia Health have uncovered a previously unknown role for the Alzheimer’s risk gene CASS4 in controlling microglial activity, suggesting that restoring its function could offer a novel strategy for slowing disease progression.
A new peer-reviewed review explores whether psychedelic compounds could influence cancer biology through neurological and immune mechanisms, whilst identifying psychological wellbeing as the most credible near-term clinical opportunity.
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.